Baystate Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Baystate Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$8.35K	Buy	800 +400	+100%	+$3.73K	﹤0.01%	768
2023 Q3	$4.08K	Hold	400	–	–	﹤0.01%	705
2023 Q2	$3.01K	Hold	400	–	–	﹤0.01%	792
2023 Q1	$3.54K	Buy	+400	New	+$3.96K	﹤0.01%	740
2019 Q3	–	Sell	-700	Closed	-$7K	–	629
2019 Q2	$7K	Hold	700	–	–	﹤0.01%	400
2019 Q1	$11K	Hold	700	–	–	﹤0.01%	377
2018 Q4	$13K	Hold	700	–	–	﹤0.01%	352
2018 Q3	$15K	Hold	700	–	–	﹤0.01%	328
2018 Q2	$17K	Hold	700	–	–	﹤0.01%	311
2018 Q1	$12K	Hold	700	–	–	﹤0.01%	340
2017 Q4	$15K	Hold	700	–	–	﹤0.01%	330
2017 Q3	$11K	Hold	700	–	–	﹤0.01%	341
2017 Q2	$22K	Hold	700	–	–	﹤0.01%	269
2017 Q1	$22K	Hold	700	–	–	﹤0.01%	261
2016 Q4	$26K	Buy	+700	New	+$27.9K	0.01%	208
2013 Q3	–	Sell	-700	Closed	-$27K	–	210
2013 Q2	$27K	Buy	+700	New	+$27.3K	0.01%	130

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Baystate Wealth Management's TEVA Position: Q4 2023 in Review

Baystate Wealth Management increased its Teva Pharmaceuticals (TEVA) stake by 100% in Q4 2023, buying an estimated $3.73K and bringing the position to 800 shares worth $8.35K. The position accounts for ﹤0.01% of the portfolio, ranked #768.

Baystate Wealth Management first reported a position in TEVA in Q2 2013 and has held it in 16 quarters since. The position peaked at $27K in Q2 2013. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

Baystate Wealth Management held 800 shares of Teva Pharmaceuticals worth $8.35K as of Q4 2023.
Baystate Wealth Management bought 400 Teva Pharmaceuticals shares in Q4 2023, an estimated $3.73K.
Teva Pharmaceuticals made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #768 holding.
Baystate Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
Baystate Wealth Management's Teva Pharmaceuticals position peaked at $27K in Q2 2013.
447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.